PRIMA-1 treatment alone did not significantly affect sensitivity to VMY in either LNCaP (p53wt) or PC3 (p53-null) cells (Supplemental Fig. S1), thus demonstrating the specificity of this compound in restoring VMY-mediated cell death to mutant p53 prostate cancer cells. This evidence concerns the gene TP53 and prostate carcinoma.